Chloroquine
- TRADE NAMES: Aralen (Sanofi-Aventis); Avloclor; Chlorquin; Emquin; Heliopar; Lagaquin; Malarivon
- INDICATIONS: Malaria, rheumatoid arthritis, lupus erythematosus
- CLASS: Antimalarial, Antimicrobial, Antiprotozoal, Covid-19 putative drug, Disease-modifying antirheumatic drug (DMARD)
- HALF-LIFE: 3–5 days
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Acitretin, Antacids, Arsenic, Cholera Vaccine, Cholestyramine, Citalopram, Dapsone, Dasatinib, Degarelix, Dolasetron, Droperidol, Ethosuximide, Furazolidone, Halofantrine, Hydroxychloroquine, Lacosamide, Lanthanum, Lapatinib, Levofloxacin, Methotrexate, Methoxsalen, Mivacurium, Moxifloxacin, Neostigmine, Nilotinib, Oxcarbazepine, Pazopanib, Penicillamine, Ribociclib, Sulfonamides, Telavancin, Telithromycin, Tiagabine, Typhoid Vaccine, Vandetanib, Vigabatrin, Voriconazole, Vorinostat, Ziprasidone
PREGNANCY CATEGORY: D
Investigated for treating COVID-19.
Please login to see the rest of this drug profile
SKIN.
HAIR.
NAILS.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OCULAR.
OTIC.
RENAL.
RESPIRATORY.
OTHER.
Page last updated 07/31/2023
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
